Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

  • Product Code
  • ILEA001187838
  • Registered date
  • 2013/10/01 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2013 Kyodo News
  • Media size
  • 1730 × 1124 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 236.37(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Novartis management replaced

    Novartis management replaced

    TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.
      Novartis management replaced

      Novartis management replaced

      TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
        Novartis management replaced

        Novartis management replaced

        TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
          Online sales of over-the-counter drugs

          Online sales of over-the-counter drugs

          TOKYO, Japan - Health, Labor and Welfare Minister Norihisa Tamura holds a press conference at the ministry in Tokyo on Nov. 6, 2013. The government said the same day that online sales of drugs moving from prescription to over-the-counter status will be banned for three years from the point of such movement in principle under new rules that could take effect next spring.
            Novartis scandal

            Novartis scandal

            TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
              Novartis scandal

              Novartis scandal

              TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                Novartis Pharma

                Novartis Pharma

                TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.
                  Data altered in Japanese research for Novartis blood pressure drug

                  Data altered in Japanese research for Novartis blood pressure drug

                  TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.
                    Mitsubishi Tanabe Pharma ordered to suspend some operations

                    Mitsubishi Tanabe Pharma ordered to suspend some operations

                    TOKYO, Japan - Mitsubishi Tanabe Pharma Corp. President Michihiro Tsuchiya (L) and Takehiko Fujii (C), president of subsidiary Bipha Corp., apologize in Tokyo on April 13, 2010, after the Health, Labor and Welfare Ministry ordered Mitsubishi Tanabe Pharma to suspend some of its pharmaceutical manufacturing and sales operations for 25 days over the alleged falsification of blood product test data. The subsidiary, which manufactured the product and falsified the data, was ordered to suspend its drug manufacturing business for 30 days.